DrDavid Chapman

Dr David Chapman is a translational physiologist with extensive expertise in airways diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Dr Chapman completed his PhD in Medicine at the Woolcock Institute of Medical Research in 2011. David was awarded an NHMRC Early Career Fellowship for 2013 to expand his research at the University of Vermont, USA.

He continued at the University of Vermont for a subsequent two years in which he integrated new lung function tests into the Centre’s animal models of respiratory disease and helped initiate an ongoing research program understanding the effect of obesity for patients with asthma. Dr Chapman returned to Australia in December 2016 to lead the Translational Airways Group at the University of Technology Sydney with a joint position in the Airway Physiology Group at the Woolcock Institute of Medical Research. He has an international reputation in lung function measurement, particularly in relation to small airway dysfunction, airway hyperresponsiveness and obesity.

His main research interests lie in understanding the way in which interventions such as obesity and tobacco use alter lung function and contribute to respiratory disease. David’s work has been recognised by multiple awards including the 2018 Ann Woolcock Award from the American Thoracic Society for “outstanding contributions and future promise in asthma research”.